Actively Recruiting
The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register
Led by Chinese University of Hong Kong · Updated on 2026-02-27
1000
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously called non-alcoholic fatty liver disease (NAFLD), is a common chronic liver condition closely linked to type 2 diabetes mellitus (T2DM). This study aims to better understand the relationship between MASLD and T2DM, focusing on the clinical progression and identifying markers that predict advanced liver fibrosis in people with these conditions. The research will establish a prospective cohort of Hong Kong Chinese individuals with T2DM and steatotic liver disease along with a biobank to support this investigation. Participants with T2DM will be recruited and undergo assessments including Fibroscan to evaluate liver health, along with collection of biomarkers and genetic markers. This study does not involve any treatment interventions but observes and collects data over time to gain insights into the disease and its progression. The study intends to follow patients long-term to observe outcomes related to liver disease and diabetes. During the study, participants will be monitored for all-cause mortality and other health events such as cardiovascular disease, heart failure, and hospitalizations over 15 years. Baseline measurements will include NT-proBNP levels and novel diagnostic markers related to metabolic dysfunction-associated steatohepatitis. Data collected from physical assessments, laboratory tests, and biobank samples will help researchers track disease progression and identify factors linked to advanced liver fibrosis.
CONDITIONS
Brief Title
The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of type 2 diabetes mellitus (T2DM)
- Age 18 years or older
- Able and willing to give informed written consent
You will not qualify if you...
- Diagnosis of type 1 diabetes
- Terminal illness such as cancer with limited life expectancy
- Any condition judged by investigators as unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline
Participants undergo biomarker and genetic marker testing along with Fibroscan to assess liver condition.
1 visit (in-person)
Duration - Up to 15 years
Participants are observed for health outcomes including mortality and cardiovascular events over an extended period.
Periodic visits as determined by clinical care
Trial Site Locations
Total: 1 location
1
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital
Hong Kong, New Territories, Hong Kong, 99977
Actively Recruiting
Research Team
A
Alice Pik Shan Kong, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here